Page 239 - Read Online
P. 239

Page 6 of 7                           Bonfiglio et al. J Cancer Metastasis Treat 2019;5:29  I  http://dx.doi.org/10.20517/2394-4722.2018.88

               this context, the expression of BMP-2 and PTX3 in BM+ lesions can provide a scientific rationale for BOLCs
               development and microcalcifications formation. Also, it is known that both BMP-2 and PTX3 are involved
               in the EMT phenomenon. Thus, it is possible to speculate that these molecules have role both in BOLCs
               generation that in the production of HA or MgHAp crystals by the BOLCs themselves.

               In conclusion, results here reported highlighted the possible use of breast microcalcifications as a negative
               prognostic marker of bone metastatic diseases. In particular, the association between elemental composition
               of breast microcalcifications and the formation of bone lesions can lay the foundation for the development of
               new in vivo diagnostic tools based on the analysis of microcalcifications and capable to predict the formation
               of bone metastasis. In this scenario, the in vivo analysis of elemental composition of microcalcifications by
               RAMAN spectroscopy could improve the clinical armamentarium available for the diagnosis and stadiation
               of breast cancer.


               DECLARATIONS
               Authors’ contributions
               Made substantial contributions to conception and design of the study and performed data analysis and
               interpretation: Bonfiglio R, Scimeca M, Bonanno E
               Performed data acquisition and performed administrative, technical, and material supports: Polidori A,
               Nazzaro C, De Silva G


               Availability of data and materials
               The data used to support the findings of this study are included within the article. Further details can be
               made available upon request.

               Financial support and sponsorship
               None.

               Conflicts of interest
               All authors declared that there are no conflicts of interest.

               Ethical approval and consent to participate
               Our study protocol was approved by independent ethical committee. Experimental procedures were carried
               out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). Specimens
               were handled and carried out in accordance with the approved guidelines.


               Consent for publication
               Not applicable.


               Copyright
               ©The Author(s) 2019.


               REFERENCES
               1.   Riihimäki M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Clinical landscape of cancer metastases. Cancer Med 2018;7:5534-
                   42.
               2.   Schneider G, Voltz R, Gaertner J. Cancer pain management and bone metastases: an update for the clinician. Breast Care (Basel)
                   2012;7:113-20.
               3.   Scimeca M, Urbano N, Bonfiglio R, Schillaci O, Bonanno E. Breast osteoblast-like cells: a new biomarker for the management of breast
                   cancer. Br J Cancer 2018;119:1129-32.
               4.   Scimeca M, Bonfiglio R, Montanaro M, Bonanno E. Osteoblast-like cells in human cancers: new cell type and reliable markers for bone
   234   235   236   237   238   239   240   241   242   243   244